JP2023513680A5 - - Google Patents
Info
- Publication number
- JP2023513680A5 JP2023513680A5 JP2022548057A JP2022548057A JP2023513680A5 JP 2023513680 A5 JP2023513680 A5 JP 2023513680A5 JP 2022548057 A JP2022548057 A JP 2022548057A JP 2022548057 A JP2022548057 A JP 2022548057A JP 2023513680 A5 JP2023513680 A5 JP 2023513680A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- group
- disorder
- hydrogen
- disorders
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024015076A JP2024054193A (ja) | 2020-02-04 | 2024-02-02 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025243928A JP2026053405A (ja) | 2020-02-04 | 2025-12-09 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062969934P | 2020-02-04 | 2020-02-04 | |
| US62/969,934 | 2020-02-04 | ||
| PCT/CA2021/050125 WO2021155470A1 (en) | 2020-02-04 | 2021-02-04 | Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024015076A Division JP2024054193A (ja) | 2020-02-04 | 2024-02-02 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025243928A Division JP2026053405A (ja) | 2020-02-04 | 2025-12-09 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023513680A JP2023513680A (ja) | 2023-04-03 |
| JP2023513680A5 true JP2023513680A5 (enExample) | 2024-02-14 |
Family
ID=77199666
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548056A Pending JP2023513679A (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2022548057A Pending JP2023513680A (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2024015076A Pending JP2024054193A (ja) | 2020-02-04 | 2024-02-02 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025172009A Pending JP2026010068A (ja) | 2020-02-04 | 2025-10-10 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025243928A Pending JP2026053405A (ja) | 2020-02-04 | 2025-12-09 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022548056A Pending JP2023513679A (ja) | 2020-02-04 | 2021-02-04 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024015076A Pending JP2024054193A (ja) | 2020-02-04 | 2024-02-02 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025172009A Pending JP2026010068A (ja) | 2020-02-04 | 2025-10-10 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
| JP2025243928A Pending JP2026053405A (ja) | 2020-02-04 | 2025-12-09 | 中枢神経系障害の治療のためのセロトニン作動性幻覚薬としてのシロシン誘導体 |
Country Status (12)
| Country | Link |
|---|---|
| US (10) | US11427604B2 (enExample) |
| EP (2) | EP4100390A4 (enExample) |
| JP (5) | JP2023513679A (enExample) |
| KR (3) | KR20220137083A (enExample) |
| CN (3) | CN115427395A (enExample) |
| AU (2) | AU2021215811A1 (enExample) |
| BR (2) | BR112022015377A2 (enExample) |
| CA (2) | CA3166933A1 (enExample) |
| IL (3) | IL327334A (enExample) |
| MX (2) | MX2022009527A (enExample) |
| PH (1) | PH12022551981A1 (enExample) |
| WO (2) | WO2021155470A1 (enExample) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| HRP20220797T1 (hr) | 2019-11-07 | 2022-10-14 | Small Pharma Ltd | Spojevi |
| MX2022009527A (es) * | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| IL297861A (en) | 2020-05-08 | 2023-01-01 | Psilera Inc | Novel compositions of matter and pharmaceutical compositions |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US11773062B2 (en) | 2021-03-22 | 2023-10-03 | Small Pharma Ltd | Deuterated compounds |
| US12042564B2 (en) | 2020-06-02 | 2024-07-23 | Cybin Uk Ltd | Therapeutic solid dosage forms |
| DK4172145T3 (da) | 2020-06-30 | 2026-07-20 | Reunion Neuroscience Inc | Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression |
| AU2021328726A1 (en) * | 2020-08-21 | 2023-03-02 | Compass Pathfinder Limited | Novel psilocin derivatives having prodrug properties |
| US11406619B2 (en) | 2020-08-28 | 2022-08-09 | Small Pharma Ltd | Injectable formulations |
| US11324762B2 (en) | 2020-10-08 | 2022-05-10 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| WO2022115944A1 (en) | 2020-12-01 | 2022-06-09 | Magicmed Industries Inc. | Carboxylated psilocybin derivatives and methods of using |
| EP4031529B1 (en) * | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| US11660289B2 (en) | 2020-12-01 | 2023-05-30 | Small Pharma Ltd. | Deuterated or partially deuterated N,N-dimethyltryptamine compounds |
| US12521370B2 (en) | 2020-12-01 | 2026-01-13 | Cybin Uk Ltd | Inhalable formulations |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
| EP4126857A1 (en) | 2021-01-15 | 2023-02-08 | Beckley Psytech Limited | Ergoline analogues |
| EP4277894A1 (en) | 2021-01-15 | 2023-11-22 | Beckley Psytech Limited | Tryptamine analogues |
| WO2022155751A1 (en) | 2021-01-22 | 2022-07-28 | Magicmed Industries Inc. | Prenylated psilocybin derivatives and methods of using |
| US11312684B1 (en) | 2021-02-10 | 2022-04-26 | Eleusis Therapeutics Us, Inc. | Pharmaceutically acceptable salts of psilocin and uses thereof |
| MX2023010317A (es) * | 2021-03-02 | 2023-11-09 | Mindset Pharma Inc | Derivados del indol como agentes serotonergicos utiles para el tratamiento de trastornos relacionados con los mismos. |
| US20220370413A1 (en) * | 2021-03-06 | 2022-11-24 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| WO2022192097A1 (en) * | 2021-03-06 | 2022-09-15 | Mind Medicine, Inc. | Formulations of psilocin that have enhanced stability |
| AU2022239825C1 (en) * | 2021-03-18 | 2026-08-13 | Cybin Irl Limited | Psilocybin analogs, salts, compositions, and methods of use |
| CN117177959A (zh) * | 2021-03-18 | 2023-12-05 | 赛本爱尔兰有限公司 | 裸头草碱类似物、盐、组合物和使用方法 |
| US20240174607A1 (en) * | 2021-03-18 | 2024-05-30 | Cybin Irl Limited | Psilocybin analogs, salts, compositions, and methods of use |
| US12611399B2 (en) | 2021-05-04 | 2026-04-28 | Definium Therapeutics US, Inc. | Movement disorders |
| KR20240013170A (ko) | 2021-05-25 | 2024-01-30 | 아타이 테라퓨틱스, 인크. | 신규 n,n-디메틸트립타민 염 및 결정질 염 형태 |
| WO2023018864A1 (en) | 2021-08-12 | 2023-02-16 | Psilosterics, Llc | Hallucinogenic and non-hallucinogenic serotonin receptor agonists and methods of making and using the same |
| KR20240065084A (ko) * | 2021-08-20 | 2024-05-14 | 테란 바이오사이언시스 인코포레이티드 | 사일로신의 전구약물 및 유도체 및 그의 용도 |
| CA3229361A1 (en) * | 2021-08-20 | 2023-02-23 | Abdelmalik Slassi | 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto |
| US11344564B1 (en) | 2021-08-20 | 2022-05-31 | Lennham Pharmaceuticals, Inc. | Method of treatment based on reduced monoamine oxidase a activity |
| US11697638B2 (en) | 2021-09-08 | 2023-07-11 | Small Pharma Ltd | 5-methoxy-N,N-dimethyltryptamine crystalline forms |
| WO2023077245A1 (en) * | 2021-11-08 | 2023-05-11 | Nova Mentis Life Science Corp. | Diagnosing, monitoring and treating neurological disease with psychoactive tryptamine derivatives and mrna measurements |
| US12318477B2 (en) | 2021-11-18 | 2025-06-03 | Cybin Uk Ltd | Injectable and inhalable formulations |
| AU2022408191B2 (en) * | 2021-12-10 | 2025-05-15 | Caamtech, Inc. | Psilocybin derivatives |
| US20250051278A1 (en) * | 2021-12-14 | 2025-02-13 | Reunion Neuroscience, Inc. | Tryptamine prodrugs |
| CA3238440A1 (en) | 2021-12-30 | 2023-07-06 | Atai Therapeutics, Inc. | Dimethyltryptamine analogues as nitric oxide delivery drugs |
| WO2023133873A1 (en) * | 2022-01-17 | 2023-07-20 | Nokia Shanghai Bell Co., Ltd. | Configuration for in-x subnetworks |
| WO2023168023A1 (en) | 2022-03-04 | 2023-09-07 | Reset Pharmaceuticals, Inc. | Co-crystals or salts comprising psilocin |
| US12065404B2 (en) | 2022-03-18 | 2024-08-20 | Enveric Biosciences Canada Inc. | C4-carboxylic acid-substituted tryptamine derivatives and methods of using |
| AU2023235712A1 (en) * | 2022-03-18 | 2024-11-07 | Enveric Biosciences Canada Inc. | C4-substituted tryptamine derivatives and methods of using |
| WO2023214404A1 (en) * | 2022-05-01 | 2023-11-09 | Short Wave Pharma Inc. | A mucoadhesive film comprising a pharmaceutically active agent and uses thereof |
| EP4522167A1 (en) | 2022-05-10 | 2025-03-19 | Mydecine Innovations Group Inc. | Novel psilocin prodrug compounds and methods of synthesizing the same |
| US12264131B2 (en) | 2022-08-19 | 2025-04-01 | Beckley Psytech Limited | Pharmaceutically acceptable salts and compositions thereof |
| CA3267605A1 (en) * | 2022-09-12 | 2024-03-21 | Bionxt Solutions Inc. | PSILOCIN DERIVATIVES BASED ON AMINO ACIDS AND CARBOHYDRATES |
| WO2024145719A1 (en) * | 2023-01-05 | 2024-07-11 | Reunion Neuroscience Inc. | Improved pharmacokinetics of tryptamine prodrugs |
| US20240269113A1 (en) * | 2023-01-24 | 2024-08-15 | Compass Pathfinder Limited | 3-(2-(DIMETHYLAMINO)ETHYL)-1H-INDOL-4-yl DERIVATIVES |
| US12396981B2 (en) | 2023-03-09 | 2025-08-26 | William Shulman | Methods of using DMT |
| EP4704833A2 (en) * | 2023-04-27 | 2026-03-11 | ATAI Therapeutics, Inc. | Alkoxy and carbamoyl quaternary amine salts as prodrugs of trpytamines |
| US12246005B2 (en) | 2023-06-13 | 2025-03-11 | Beckley Psytech Limited | 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations |
| CN121793958A (zh) * | 2023-06-27 | 2026-04-03 | 帕多瓦大学 | 使用二甲-4-羟色胺磷酸的联合疗法 |
| JP2026524104A (ja) | 2023-06-28 | 2026-07-17 | サイロ プロプリエタリー リミテッド | 化合物 |
| EP4735441A1 (en) | 2023-06-28 | 2026-05-06 | Psylo Pty Ltd | Pyrrolopyridine compounds for the treatment of mental illnesses |
| EP4746873A1 (en) * | 2023-07-19 | 2026-05-27 | ATAI Therapeutics, Inc. | Novel prodrugs and conjugates of dimethyltryptamine and methods of using the same |
| TW202519206A (zh) * | 2023-11-06 | 2025-05-16 | 大陸商宜昌人福藥業有限責任公司 | 一種n,n-二甲基色胺衍生物及其藥物組合物、製備方法和用途 |
| WO2025104491A1 (en) | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| US12310974B1 (en) | 2023-12-19 | 2025-05-27 | Samuel Aballea | Method of treating post-traumatic stress disorder with carpipramine |
| WO2025238416A1 (en) * | 2024-05-16 | 2025-11-20 | Mindset Pharma Inc. | Indole derivatives, uses and compositions thereof |
| WO2026024591A1 (en) * | 2024-07-22 | 2026-01-29 | Reunion Neuroscience, Inc. | Tryptamine prodrug solid forms |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1242318A (en) | 1913-12-20 | 1917-10-09 | Sam Brest | Ash sifter and receptacle. |
| US3075992A (en) | 1958-09-12 | 1963-01-29 | Sandoz Ltd | Esters of indoles |
| US3078214A (en) * | 1958-09-12 | 1963-02-19 | Sandoz Ag | Treatment of mental disturbances with esters of indoles |
| CH373381A (de) | 1959-07-13 | 1963-11-30 | Sandoz Ag | Verfahren zur Herstellung neuer basischer Indol-Derivate |
| CH386422A (de) | 1960-03-30 | 1965-01-15 | Sandoz Ag | Verfahren zur Herstellung neuer Ester der Indol-Reihe |
| GB981192A (en) | 1960-03-30 | 1965-01-20 | Westminster Bank Ltd | Improvements in or relating to 4 hydroxytryptamine esters |
| GB933286A (en) | 1961-03-23 | 1963-08-08 | Lodge Cottrell Ltd | Improvements in and relating to electro-precipitation |
| CH414639A (de) * | 1961-10-20 | 1966-06-15 | Sandoz Ag | Verfahren zur Herstellung neuer heterocyclischer Verbindungen |
| US3202675A (en) | 1961-10-26 | 1965-08-24 | Sterling Drug Inc | 1-benzyl-2, 5-bis (chloromethyl) pyrrolidine and acid-addition salts thereof |
| BE615395A (enExample) | 1962-03-21 | |||
| GB990092A (en) | 1962-10-24 | 1965-04-22 | Roche Products Ltd | Novel indole derivatives and a process for the manufacture thereof |
| WO2005062985A2 (en) * | 2003-12-23 | 2005-07-14 | American Bioscience, Inc. | Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications |
| WO2006047032A2 (en) * | 2004-09-27 | 2006-05-04 | Organix, Inc. | Indole compounds useful as serotonin selective agents |
| US7429575B2 (en) | 2006-01-10 | 2008-09-30 | Yu Ruey J | N-(phosphonoalkyl)-amino acids, derivatives thereof and compositions and methods of use |
| EP2014662A1 (de) * | 2007-07-12 | 2009-01-14 | Bayer Schering Pharma Aktiengesellschaft | Indolylalkylthienopyrimidylamine als Modulatoren des EP2-Rezeptors |
| US20090318527A1 (en) * | 2008-02-11 | 2009-12-24 | Howard Sard | Indole compounds and methods of use thereof |
| EP2149552A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149551A1 (de) * | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| US8912220B2 (en) * | 2009-08-10 | 2014-12-16 | Galenea Pharmaceuticals | Compounds and methods of use thereof |
| RU2016129380A (ru) * | 2013-12-20 | 2018-01-25 | СИГНАЛ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Замещенные диаминопиримидильные соединения, их композиции и способы лечения с их участием |
| ES2882588T3 (es) | 2015-03-31 | 2021-12-02 | Turtle Bear Holdings Llc | Actividad antiviral de setas medicinales y sus constituyentes activos |
| WO2016205304A1 (en) * | 2015-06-16 | 2016-12-22 | Signal Pharmaceuticals, Llc | Methods of treatment using substituted diaminopyrimidyl compounds |
| CZ307719B6 (cs) | 2015-12-31 | 2019-03-20 | Vysoká škola chemicko-technologická v Praze | Použití derivátu tryptaminu |
| US20180021326A1 (en) | 2016-07-23 | 2018-01-25 | Paul Edward Stamets | Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin |
| CA3077053A1 (en) * | 2017-09-27 | 2019-04-04 | Ohio State Innovation Foundation | Methods and compositions for inhibition of stat3 |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US11723894B2 (en) * | 2017-10-26 | 2023-08-15 | Terran Biosciences, Inc. | Combination product for the treatment of neurological and/or psychiatric disorders |
| US12090145B2 (en) | 2018-08-20 | 2024-09-17 | Yale University | Combination therapy for treating or preventing depression or other mood diseases |
| MX2021009037A (es) | 2019-01-30 | 2021-10-13 | Diamond Therapeutics Inc | Composiciones y metodos para el manejo de trastornos. |
| US12616706B2 (en) | 2019-03-07 | 2026-05-05 | Arbormentis LLC | Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations |
| GB201907871D0 (en) | 2019-06-03 | 2019-07-17 | Small Pharma Ltd | Therapeutic compositions |
| HRP20220797T1 (hr) | 2019-11-07 | 2022-10-14 | Small Pharma Ltd | Spojevi |
| US20230021957A1 (en) | 2019-12-04 | 2023-01-26 | Neonmind Biosciences Inc. | Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder |
| MX2022009527A (es) * | 2020-02-04 | 2022-11-16 | Mindset Pharma Inc | Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc. |
| US20210236523A1 (en) | 2020-02-05 | 2021-08-05 | Yale University | Psychedelic treatment for headache disorders |
| KR20230005367A (ko) | 2020-05-04 | 2023-01-09 | 트러스티즈 오브 터프츠 칼리지 | 뇌 전달을 위한 합성 지질-유사 물질 |
| IL312785B2 (en) | 2020-05-19 | 2026-06-01 | Cybin Irl Ltd | Deuterated tryptamine derivatives and methods of use |
| US20220169606A1 (en) | 2020-12-01 | 2022-06-02 | Small Pharma Ltd. | Compositions and compounds for bioanalysis |
| WO2021116503A2 (en) | 2020-06-02 | 2021-06-17 | Small Pharma Ltd | Deuterated compounds |
| US20220168274A1 (en) | 2020-12-01 | 2022-06-02 | Small Pharma Ltd. | Parenteral Formulation |
| DK4172145T3 (da) | 2020-06-30 | 2026-07-20 | Reunion Neuroscience Inc | Tryptamin-prodrugs som serotonin-receptor-aktivatorer til behandling af f.eks. depression |
| JP2023539113A (ja) | 2020-08-18 | 2023-09-13 | サイビン アイアールエル リミテッド | フェネチルアミン誘導体、組成物およびその使用方法 |
| AU2021328726A1 (en) * | 2020-08-21 | 2023-03-02 | Compass Pathfinder Limited | Novel psilocin derivatives having prodrug properties |
| EP4138818B1 (en) | 2020-08-28 | 2024-08-21 | Cybin UK Ltd | Injectable formulation |
| US11324762B2 (en) | 2020-10-08 | 2022-05-10 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| US11000534B1 (en) | 2020-10-08 | 2021-05-11 | Lennham Pharmaceuticals, Inc. | Deuterated derivatives of psilocybin and uses thereof |
| EP4031529B1 (en) | 2020-12-01 | 2023-09-27 | Small Pharma Ltd | Deuterated or partially deuterated n,n-dimethyltryptamine compounds |
| EP4255421A1 (en) | 2020-12-01 | 2023-10-11 | Small Pharma Ltd | Inhalable formulations |
| WO2022120181A1 (en) * | 2020-12-03 | 2022-06-09 | Mydecine Innovations Group Inc. | Novel psilocin analog compositions and methods of synthesizing the same |
| CA3201913A1 (en) * | 2020-12-09 | 2022-06-16 | Andrew R. Chadeayne | Dialkyl trytamines and their therapeutic uses |
| JP2024500397A (ja) * | 2020-12-18 | 2024-01-09 | コンパス パスファインダー リミテッド | 治療用途のための修飾インドールアルカロイド |
-
2021
- 2021-02-04 MX MX2022009527A patent/MX2022009527A/es unknown
- 2021-02-04 JP JP2022548056A patent/JP2023513679A/ja active Pending
- 2021-02-04 WO PCT/CA2021/050125 patent/WO2021155470A1/en not_active Ceased
- 2021-02-04 CN CN202180026581.4A patent/CN115427395A/zh active Pending
- 2021-02-04 EP EP21750671.6A patent/EP4100390A4/en active Pending
- 2021-02-04 BR BR112022015377A patent/BR112022015377A2/pt unknown
- 2021-02-04 IL IL327334A patent/IL327334A/en unknown
- 2021-02-04 CA CA3166933A patent/CA3166933A1/en active Pending
- 2021-02-04 EP EP21751268.0A patent/EP4100391A4/en active Pending
- 2021-02-04 PH PH1/2022/551981A patent/PH12022551981A1/en unknown
- 2021-02-04 WO PCT/CA2021/050123 patent/WO2021155468A1/en not_active Ceased
- 2021-02-04 JP JP2022548057A patent/JP2023513680A/ja active Pending
- 2021-02-04 KR KR1020227030616A patent/KR20220137083A/ko not_active Ceased
- 2021-02-04 MX MX2022009526A patent/MX2022009526A/es unknown
- 2021-02-04 KR KR1020247004116A patent/KR20240023678A/ko not_active Ceased
- 2021-02-04 KR KR1020227030603A patent/KR20220137081A/ko not_active Ceased
- 2021-02-04 CN CN202180026575.9A patent/CN115397810A/zh active Pending
- 2021-02-04 AU AU2021215811A patent/AU2021215811A1/en active Pending
- 2021-02-04 AU AU2021217424A patent/AU2021217424A1/en active Pending
- 2021-02-04 CN CN202310101242.9A patent/CN115974757A/zh active Pending
- 2021-02-04 BR BR112022015375A patent/BR112022015375A2/pt unknown
- 2021-02-04 CA CA3166936A patent/CA3166936A1/en active Pending
- 2021-07-28 US US17/387,845 patent/US11427604B2/en active Active
- 2021-07-28 US US17/387,883 patent/US20220024956A1/en active Pending
-
2022
- 2022-05-13 US US17/743,718 patent/US11597738B2/en active Active
- 2022-06-06 US US17/833,341 patent/US11591353B2/en active Active
- 2022-08-04 IL IL295364A patent/IL295364B2/en unknown
- 2022-08-04 IL IL295371A patent/IL295371B2/en unknown
- 2022-12-12 US US18/079,617 patent/US12054505B2/en active Active
-
2023
- 2023-01-27 US US18/102,359 patent/US20230167141A1/en not_active Abandoned
- 2023-02-15 US US18/109,890 patent/US20230203070A1/en not_active Abandoned
-
2024
- 2024-02-02 JP JP2024015076A patent/JP2024054193A/ja active Pending
- 2024-05-30 US US18/678,114 patent/US12378266B2/en active Active
- 2024-12-16 US US18/982,452 patent/US20250388611A1/en active Pending
-
2025
- 2025-06-11 US US19/235,150 patent/US20260116901A1/en active Pending
- 2025-10-10 JP JP2025172009A patent/JP2026010068A/ja active Pending
- 2025-12-09 JP JP2025243928A patent/JP2026053405A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022545633A5 (enExample) | ||
| JP2024520481A5 (enExample) | ||
| JP2024050527A5 (enExample) | ||
| JP2023513679A5 (enExample) | ||
| TW548274B (en) | Dihydropyrimidines having hepatitis B therapeutic efficacy | |
| JP2023512821A5 (enExample) | ||
| JP4724665B2 (ja) | キノリノン化合物を合成する方法 | |
| JP2023520924A5 (enExample) | ||
| JP6285440B2 (ja) | 融合二環式スルファモイル誘導体並びにｂ型肝炎の治療のための薬剤としてのその使用 | |
| JP2024166311A (ja) | 化合物、組成物、及び、方法 | |
| JP7697954B2 (ja) | Ｋｖ１．３カリウムシェーカーチャネル遮断薬としてのアリールメチレン芳香族化合物 | |
| JP2023520916A5 (enExample) | ||
| JP6047556B2 (ja) | Ｌｒｒｋ２キナーゼ活性の阻害剤 | |
| JP2023533203A5 (enExample) | ||
| JP2014526435A5 (enExample) | ||
| JP2007510668A5 (enExample) | ||
| JP2008540637A5 (enExample) | ||
| JP2016515096A (ja) | スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用 | |
| JP2022534709A5 (enExample) | ||
| JP2022534704A5 (enExample) | ||
| JP2012505234A5 (enExample) | ||
| RU2012134306A (ru) | Азотосодержащие производные гетероарилов | |
| JP2011517440A (ja) | 中枢神経系障害を処置するためのアザインドール化合物 | |
| JP2016507502A5 (enExample) | ||
| WO2020167994A1 (en) | Compounds, compositions and methods |